natgillin/translations-raw huggingface dataset:
If a dose up to 5 microgram iloprost is indicated, again dosing intervals of 3-4 hours should be chosen initially and shortened according to individual tolerability. 
Ako je indicirana doza do 5 mikrograma iloprosta, isprva je ponovno potrebno odabrati intervale od 3-4 sata uz skraćivanje sukladno pojedinačnoj podnošljivosti.
Depending on the type of device used and dose prescribed, 1 ml or 2 ml of Ventavis 10 microgram/ml are appropriate. 
Ovisno o tipu uređaja i propisanoj dozi, prikladna je primjena 1 ml ili 2 ml lijeka Ventavis 10 mikrograma/ml.
Any Ventavis solution remaining in the nebuliser after inhalation must be thrown away. 
Sva Ventavis otopina koja preostane u nebulizatoru nakon inhalacije mora se baciti.
In embryo- and foetotoxicity studies in rats continuous intravenous administration of iloprost led to anomalies of single phalanges of the forepaws in a few foetuses/pups without dose dependence. 
U ispitivanjima toksičnosti za embrije i fetuse štakora kontinuirana intravenska primjena iloprosta dovela je do anomalije jednog članka prsta na prednjim šapama u nekoliko fetusa/mladunčadi neovisno o dozi.
You may also experience a decrease or an increase in blood pressure, bradycardia (reduced heart rate), tachycardia (increased heart rate), vomiting, diarrhoea or limb pain. 
Također bi Vam se moglo javiti sniženje ili povišenje krvnog tlaka, bradikardija (usporeni ritam srca), tahikardija (ubrzani ritam srca), povraćanje, proljev ili bolovi u udovima.
If you tend to experience fainting episodes, avoid any exceptional straining, for example during physical exertion; it might be useful to inhale Ventavis before. 
Ako ste skloni epizodama nesvjestica, izbjegavajte bilo kakav izniman napor, primjerice tijekom tjelesne aktivnosti, a prije takvih aktivnosti može biti korisna inhalacija lijeka
If you forget to use Ventavis 
Ako ste zaboravili primijeniti Ventavis
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava krvarenja*§
• 300 ampoules. 
• 300 ampula.
What Ventavis is and what it is used for What Ventavis is 
Što je Ventavis i za što se koristi Što je Ventavis
If you stop taking Ventavis 
Ako prestanete primjenjivati Ventavis
Room ventilation 
Prozračivanje prostorije
A careful monitoring of the patients taking anticoagulants or other inhibitors of platelet aggregation according to common medical practice is recommended. 
Bolesnike koji uzimaju antikoagulanse ili druge inhibitore agregacije trombocita preporučuje se pomno nadzirati u skladu s uobičajenom medicinskom praksom.
85 mmHg for the upper value) then therapy with Ventavis should not be started. 
85 mmHg), tada ne biste trebali započeti liječenje lijekom Ventavis.
Frequently observed symptoms following overdose are dizziness, headache, flushing, nausea, jaw pain or back pain. 
Učestalo primijećeni simptomi nakon predoziranja su omaglica, glavobolja, naleti crvenila, mučnina, bol u čeljusti ili bol u leđima.
In the iloprost group, the mean change from baseline after 12 weeks of treatment in the 6-minute walking distance was an increase of 22 metres (-3.3 metres in the placebo group, no data imputation for death or missing values). 
U skupini koja je primala iloprost prosječna promjena u udaljenosti hodanja tijekom 6 minuta u odnosu na početnu vrijednost nakon 12 tjedana liječenja bila je povećanje za 22 metra (-3,3 metra u skupini koja je primala placebo bez korekcije podataka za smrtne ishode ili nedostajuće vrijednosti).
First dosing with 2.5 microgram should be done even if patients had already been stable on 5 microgram inhaled with an alternative device (see section 4.2). 
Potrebno je da prva doza iloprosta bude 2,5 mikrograma čak i ako je bolesnik već stabilan na dozi od 5 mikrograma inhaliranih putem drugog uređaja (vidjeti dio
Cmax and AUC (0-tlast) of iloprost after inhalation with Breelib were, however, still in the range of values observed with Ventavis 10 microgram/ml using other inhalers across different studies. 
Cmax i AUC (0-tlast) iloprosta nakon inhalacije pomoću uređaja Breelib bile su ipak i dalje u rasponu vrijednosti zabilježenih uz primjenu lijeka Ventavis 10 mikrograma/ml pomoću drugih inhalatora u različitim ispitivanjima.
“How to use Ventavis”). 
"Kako primjenjivati Ventavis").
Ventavis10 microgram/ml is available in the following packs: 
Ventavis 10 mikrograma/ml je dostupan u sljedećim pakiranjima:
There is no need to alter the dose in patients with mild or moderate kidney problems (patients with a creatinine clearance > 30 ml/min). 
Nema potrebe za izmjenom doze u bolesnika s blagim ili umjerenim problemima s bubrezima (bolesnici s klirensom kreatinina > 30 ml/min).
Patients stabilised on one nebuliser should not switch to another nebuliser without supervision by the treating physician as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and delivery of the solution that may be faster (see section 5.2). 
Bolesnici stabilizirani na jednom nebulizatoru ne smiju prelaziti na drugi nebulizator bez nadzora nadležnog liječnika jer je dokazano da različiti nebulizatori stvaraju aerosole čija se fizička svojstva blago razlikuju, a isporuka otopine može biti brža (vidjeti dio 5.2).
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin, ATC code: B01AC11 
Farmakoterapijska skupina: Antitrombotici, inhibitori agregacije trombocita izuzev heparina,
The risk of bleeding may be increased in patients when potential inhibitors of platelet aggregation or anticoagulants are given concomitantly (see section 4.5). 
Rizik od krvarenja može biti povećan u bolesnika kad se istodobno primjenjuju potencijalni inhibitori agregacije trombocita ili antikoagulansi (vidjeti dio 4.5).
• Medicines that thin the blood or inhibit blood clotting, this includes acetylsalicylic acid (ASA - a compound found in many medicines that lower fever and relieve pain), heparin, coumarin-type anticoagulants, such as warfarin or phenprocoumon, non-steroidal anti-inflammatory drugs, non-selective phosphodiesterase inhibitors, such as pentoxifylline, selective phosphodiesterase 3 (PDE 3) inhibitors, such as cilostazol or anagrelide, ticlopidine, clopidogrel, glycoprotein IIb/IIIa antagonists, such as o abciximab, o eptifibatide, o tirofiban, defibrotide. 
• lijekove koji razrjeđuju krv ili sprečavaju zgrušavanje krvi, što uključuje acetilsalicilatnu kiselinu (ASK - tvar koja se nalazi u mnogim lijekovima za snižavanje tjelesne temperature i ublažavanje boli), heparin, kumarinske antikoagulanse, kao što su varfarin ili fenprokumon, nesteroidne protuupalne lijekove, neselektivne inhibitore fosfodiesteraze, kao što je pentoksifilin, selektivne inhibitore fosfodiesteraze 3 (PDE 3), kao što su cilostazol ili anagrelid,
• swelling of the limbs (peripheral oedema) 
• oticanje udova (periferni edem)
The measured MMAD of the aerosol droplets was 2.1 micrometres. 
Izmjereni MMAD kapljica aerosola bio je 2,1 mikrometara.
The mean clearance of iloprost is estimated to be 10 ml/minute/kg. 
Procijenjeni prosječni klirens iloprosta iznosio je 10 ml/minuta/kg.
Ventavis therapy should only be initiated by a physician experienced in treatment of pulmonary hypertension. 
Terapiju lijekom Ventavis smije propisati samo liječnik s iskustvom u liječenju plućne hipertenzije.
For each inhalation session you should use a new ampoule of Ventavis. 
Za svaku inhalaciju potrebno je primijeniti novu ampulu lijeka Ventavis.
A potential risk to the breast-feeding child cannot be excluded and it is preferable to avoid breast-feeding during Ventavis therapy. 
Mogući rizik za dojenče ne može se isključiti te se preporučuje izbjegavati dojenje za vrijeme liječenja lijekom Ventavis.
The nebulising device delivers 5 microgram iloprost at the mouthpiece. 
Nebulizator isporučuje 5 mikrograma ilioprosta u nastavku za usta.
Initially, doses of 2.5 microgram iloprost should be administered using Ventavis 10 microgram/ml with dosing intervals of 3-4 hours (corresponds to administration of max. 6 times per day). 
Isprva je potrebno davati doze od 2,5 mikrograma iloprosta primjenom lijeka Ventavis 10 mikrograma/ml u intervalima od 3-4 sata (što odgovara primjeni od maksimalno 6 puta na dan).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KARTONSKA KUTIJA
Switching to the Breelib nebuliser 
Prelazak na nebulizator Breelib
Breelib is a small handheld, battery-powered, breath activated, vibrating mesh technology system. 
Breelib je mali, ručni, nebulizatorski sustav s baterijskom napajanjem s tehnologijom vibrirajuće mrežice koji se aktivira udahom.
− Conditions where the effects of Ventavis on platelets might increase the risk of haemorrhage 
- Stanja pri kojima učinci lijeka Ventavis na trombocite mogu povećati rizik od krvarenja (npr.
In the iloprost group the NYHA class was improved in 26% of patients (placebo: 15%) (p = 0.032), unchanged in 67.7% of patients (placebo: 76%) and deteriorated in 6.3% of patients (placebo: 9%). 
(p = 0,032), u 67,7% bolesnika nije bilo promjene (placebo: 76%), dok je u 6,3% bolesnika došlo do pogoršanja stanja (placebo: 9%).
Ventavis nebuliser solution should not come into contact with skin and eyes; oral ingestion of Ventavis solution should be avoided. 
Kontakt s kožom i očima, ingestija Ventavis otopina za nebulizator ne smije doći u kontakt s kožom ni očima; mora se izbjeći ingestija otopine Ventavis.
• 168 (4x42) ampoules 
• 168 (4 x 42) ampula
Data with intravenously administered iloprost indicated that the elimination is reduced in patients with hepatic dysfunction and in patients with renal failure requiring dialysis (see section 5.2). 
Podaci o intravenskoj primjeni iloprosta ukazuju na to da je eliminacija smanjena u bolesnika s jetrenom disfunkcijom i u bolesnika sa zatajenjem bubrega na dijalizi (vidjeti dio 5.2).
Ventavis 20 microgram/ml is double the concentration of Ventavis 10 microgram/ml. 
Ventavis 20 mikrograma/ml ima dvostruku koncentraciju u odnosu na Ventavis 10 mikrograma/ml.
• 90 ampoules 
• 90 ampula
The haemodynamics observed suggest an acute response with preferential effect of inhaled treatment on the pulmonary vessels. 
Primijećeni hemodinamički podaci upućuju na akutni odgovor uz pretežiti učinak liječenja inhaliranjem na plućne žile.
If you cannot tolerate inhalation of Ventavis 20 microgram/ml talk to your doctor who may decide that you should take Ventavis 10 microgram/ml (1 ml ampoule). 
Ako ne možete podnijeti inhalaciju lijekaVentavis 20 mikrograma/ml obratite se svom liječniku koji može odlučiti da trebate uzimati Ventavis 10 mikrograma/ml (ampula od 1 ml).
To obtain the optimal droplet size for the administration of Ventavis 10 microgram/ml nebuliser solution the green baffle plate should be used. 
Da bi se postigla optimalna veličina kapljica za primjenu Ventavis 10 mikrograma/ml otopine za nebulizator, potrebno je koristiti zelenu ploču.
Part of a multipack containing 300 ampoules with 2 ml. 
Dio višestrukog pakiranja koje sadrži 300 ampula s 2 ml.
Part of a multipack containing 90 ampoules with 2 ml. 
Dio višestrukog pakiranja koje sadrži 90 ampula s 2 ml.
• Ventavis 20 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib or the I-Neb AAD nebuliser). 
• Ventavis 20 mikrograma/ml otopina za nebulizator inhalira se pomoću nebulizatora kojeg Vam je propisao liječnik (Breelib ili I-Neb AAD nebulizator).
Pulmonary veno-occlusive disease 
Venookluzivna bolest pluća
Patients stabilised on one nebuliser should not switch to another nebuliser without close supervision by the treating doctor as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and may have faster delivery of the solution (see section 5.2 of the Summary of Product Characteristics). 
Bolesnici stabilizirani na jednom nebulizatoru ne bi smjeli prelaziti na korištenje drugog nebulizatora bez pomnog nadzora svog liječnika jer je dokazano da različiti nebulizatori stvaraju aerosole čija se fizička svojstva blago razlikuju i koji mogu brže isporučiti otopinu (vidjeti dio 5.2 sažetka opisa svojstava lijeka).
Pharmacokinetics of iloprost were investigated in a randomised, crossover study with 27 patients, stable on Ventavis 10 microgram/ml inhaled with I-Neb, following inhalation of single doses of 2.5 or 5 microgram iloprost using the Breelib or the I-Neb AAD nebuliser. 
Farmakokinetika iloprosta ispitivana je u randomiziranom križnom ispitivanju na 27 bolesnika stabilnih na lijeku Ventavis 10 mikrograma/ml inhaliranom s I-Neb nebulizatorom, nakon inhalacije jednokratnih doza od 2,5 ili 5 mikrograma iloprosta pomoću nebulizatora Breelib ili I-Neb AAD.
Hypotension, an increase of blood pressure, bradycardia or tachycardia, vomiting, diarrhoea and limb pain might also be possible. 
Mogući su također i hipotenzija, povišeni krvni tlak, bradikardija ili tahikardija, povraćanje, proljev te bolovi u udovima.
Bayer Oy Puh/Tel: +358 20 785 21 
Puh/Tel: +358 20 785 21
Comparable systemic exposures (AUC (0-tlast)) and approximately 30% higher maximum serum concentrations (Cmax) were found following inhalation of Ventavis 20 microgram/ml compared to Ventavis 10 microgram/ml which was in line with the observed shorter inhalation time using Ventavis 20 microgram/ml. 
Zabilježene su usporedive sistemske izloženosti (AUC [0-tlast])) i približno 30% više maksimalne koncentracije u serumu (Cmax) nakon inhalacije lijeka Ventavis 20 mikrograma/ml u odnosu na Ventavis 10 mikrograma/ml, što je bilo u skladu s opaženim kraćim trajanjem inhalacije kad se primjenjivao Ventavis 20 mikrograma/ml.
Your doctor will supervise your treatment when you start using the Breelib nebuliser to ensure that you tolerate dose and speed of inhalation well. 
Na početku korištenja nebulizatora Breelib, liječnik će nadzirati Vaše liječenje kako bi se uvjerio da dobro podnosite dozu i brzinu inhalacije.
The risk of bleeding may be increased in patients when inhibitors of platelet aggregation or anticoagulants are given at the same time (see also section 2). 
Rizik od krvarenja može biti povećan u bolesnika koji istodobno uzimaju i inhibitore agregacije trombocita ili antikoagulanse (pogledajte i dio 2.).
For administration with the Breelib or the I-Neb. 
Za primjenu pomoću nebulizatora Breelib ili I-Neb.
Diarrhoea Vomiting Mouth and tongue irritation including pain 
Poremećaji probavnog sustava mučnina proljev povraćanje iritacija usta i jezika uključujući i bol disgeuzija
• 100 ampoules 
• 100 ampula
Poligono Industrial Santa Rosa s/n 28806 Alcalá de Henares Madrid 
28806 Alcalá de Henares
• pain in jaw/spasm of the jaw muscles (trismus) 
• mučnina • bol u čeljusti / grč mišića čeljusti (trizmus)
After each inhalation session, any solution remaining in the nebuliser should be discarded. 
Nakon svake inhalacije, ostatak otopine u nebulizatoru mora se baciti.
Excipients: trometamol, ethanol 96%, sodium chloride, hydrochloric acid (for pH adjustment), water for injections. 
Pomoćne tvari: trometamol, etanol 96%, natrijev klorid, kloridna kiselina (za podešavanje pH), voda za injekcije.
The Mass Median Aerodynamic Diameter (MMAD) of the aerosol measured using I-Neb nebulising systems equipped with power level 10 disc was similar between Ventavis 20 microgram/ml (golden programme) and Ventavis 10 microgram/ml (purple programme) nebuliser solutions (i.e.: around 2 micrometres) but with faster delivery when using Ventavis 20 microgram/ml. 
Medijan mase aerodinamičkog promjera (MMAD) aerosola izmjeren pri upotrebi I-Neb nebulizatorskog sustava opremljenog diskom snage razine 10 bio je sličan za Ventavis 20 mikrograma/ml (zlatni program) i Ventavis 10 mikrograma/ml (ljubičasti program) otopine za nebulizator (tj. MMAD je iznosio oko 2 mikrometra), ali s bržim isporučivanjem kada se koristi Ventavis 20 mikrograma/ml.
mouthpiece and 1 medication chamber). 
1 nastavak za usta i 1 komoru za lijek).
In the iloprost group, the median daily inhaled dose was 30 microgram (range 12.5 to 45 microgram/day). 
30 mikrograma (raspon od 12,5 do 45 mikrograma dnevno).
Be sure to ventilate or air the room in which you have taken your Ventavis treatment. 
Svakako ventilirajte ili prozračite prostoriju u kojoj ste primijenili Ventavis.
• Venta-Neb nebuliser (2 ml ampoule with white and pink rings) 
• Nebulizator Venta-Neb (ampula od 2 ml s bijelim i ružičastim prstenom)
To minimise accidental exposure, it is recommended to keep the room well ventilated. 
Kako bi se nehotično izlaganje svelo na najmanju mjeru, preporučuje se dobro prozračivati prostoriju.
Τηλ: +30 210 61 87 500 
Bayer Ελλάς ΑΒΕΕ Τηλ: +30 210 61 87 500
• 30 ampoules 
• 30 ampula
If you are unable to tolerate the 5 microgram dose, the dose should be reduced to 2.5 microgram. 
Ako ne možete podnijeti dozu od 5 mikrograma, dozu je potrebno smanjiti na 2,5 mikrograma.
Ventavis should only be initiated and monitored by a physician experienced in the treatment of pulmonary hypertension. 
Liječenje lijekom Ventavis smije započeti i pratiti samo liječnik s iskustvom u liječenju plućne hipertenzije.
Bronchospasm* (see section 4.4) / Wheezing 
(vidjeti dio 4.4) / piskanje
• fast heartbeat (tachycardia) 
• ubrzani otkucaji srca (tahikardija)
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS AMPOULE WITH 1 ML 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE AMPULA S 1 ML
• Bronchospasm (sudden constriction of the muscles in the walls of the small airways) and wheezing (see also section 2 “Warnings and precautions”) 
Nepoznato (ne može se procijeniti iz dostupnih podataka): • Bronhospazam (iznenadno stezanje mišića u stijenkama malih dišnih putova) i piskanje pri disanju (pogledajte također dio 2. "Upozorenja i mjere opreza").
Just before you start to inhale, break the glass ampoule and pour the solution into the medication chamber following the instructions for use of the nebuliser. 
Neposredno prije početka inhalacije, prelomite staklenu ampulu i sav njezin sadržaj izlijte u komoru za lijek slijedeći upute za uporabu nebulizatora.
It cannot be excluded that this is also relevant to humans on prolonged Ventavis therapy. 
Ne može se isključiti jednak učinak u ljudi u slučaju dugotrajnog liječenja lijekom Ventavis.
To obtain the optimal droplet size for the administration of Ventavis the green baffle plate should be used. 
Da bi se postigla optimalna veličina kapljica za primjenu lijeka Ventavis, potrebno je koristiti zelenu ploču.
Syncope is a common symptom of the disease itself and can also occur under therapy. 
Sinkopa je uobičajeni simptom same bolesti, a može se pojaviti i tijekom liječenja.
In a study with intravenous infusion of iloprost, patients with end-stage renal failure undergoing intermittent dialysis treatment are shown to have a significantly lower clearance (mean CL = 5 ± 2 ml/minute/kg) than that observed in patients with renal failure not undergoing intermittent dialysis treatment (mean CL = 18 ± 2 ml/minute/kg). 
U ispitivanju s intravenskom infuzijom iloprosta u bolesnika sa zatajenjem bubrega u završnoj fazi na intermitentnoj dijalizi uočen je značajno niži klirens (srednja vrijednost CL = 5 ± 2 ml/minuta/kg) od onog koji je uočen u bolesnika sa zatajenjem bubrega koji se ne podvrgavaju intermitentnoj dijalizi
Tachycardia Palpitations 
Srčani poremećaji tahikardija palpitacije
• hypersensitivity (i.e. allergy) 
• smanjen broj trombocita (trombocitopenija) • preosjetljivost (tj. alergija)
The use of Ventavis is not recommended in patients with unstable pulmonary hypertension, with advanced right heart failure. 
4.4 Posebna upozorenja i mjere opreza pri uporabi Upotreba lijeka Ventavis ne preporučuje se bolesnicima s nestabilnom plućnom hipertenzijom s uznapredovalim zatajenjem desne strane srca.
Estimated inhalation time 
Procijenjeno trajanje inhalacije
Multipack containing 90 (3x30) or 300 (10x30) ampoules. 
Višestruko pakiranje sadrži 90 (3 x 30) ili 300 (10 x 30) ampula.
Patients initiating Ventavis treatment or switching from an alternative device to Breelib should be closely supervised by the treating physician to ensure that dose and speed of inhalation are well tolerated. 
Potreban je pomni nadzor bolesnika koji započinju liječenje lijekom Ventavis ili prelaze s drugog nebulizatora na Breelib od strane nadležnog liječnika kako bi se osiguralo da se doza i brzina inhalacije dobro podnose.
Ampoules with 1 ml nebuliser solution (for the use of Breelib or I-Neb AAD): Packages containing: 
Ampule s 1 ml otopine za nebulizator (za primjenu pomoću uređaja Breelib ili I-Neb AAD): Pakiranja sadrže:
Your doctor will advise you. 
to će Vas uputiti Vaš liječnik.
If inhalation with Ventavis 10 microgram/ml is well tolerated, the dose should be increased by using Ventavis 20 microgram/ml. 
Ako se inhalacija lijeka Ventavis 10 mikrograma/ml dobro podnosi, dozu je potrebno povećati primjenom lijeka Ventavis 20 mikrograma/ml.
• stop the inhalation session 
• prekinite s inhalacijom
In case of poor tolerability of Ventavis 20 microgram/ml, the dose should be reduced by using 1 ml ampoule of Ventavis 10 microgram/ml (see section 4.4). 
U slučaju slabog podnošenja lijeka Ventavis 20 mikrograma/ml, doza se mora smanjiti primjenom ampule od 1 ml lijeka Ventavis 10 mikrograma/ml (vidjeti dio 4.4).
6.5 Nature and contents of container Ventavis 10 microgram/ml nebuliser solution 
6.5 Vrsta i sadržaj spremnika Ventavis 10 mikrograma/ml otopina za nebulizator
• I-Neb AAD nebuliser (1 ml ampoule with white and yellow rings) 
• Nebulizator I-Neb AAD (ampula od 1 ml s bijelim i žutim prstenom)
Bayer AB Tel: +46 (0) 8 580 223 00 
Tel: +46 (0) 8 580 223 00
Just before you start to inhale, take the yellow-red colour coded ampoule of Ventavis 20 microgram/ml, break the glass ampoule and pour the complete contents of 1 ml into the nebuliser medication golden chamber. 
Neposredno prije početka inhalacije, uzmite ampulu lijeka Ventavis 20 mikrograma/ml označenu žutom i crvenom bojom, prelomite staklenu ampulu i sav njezin sadržaj od 1 ml izlijte u komoru za lijek zlatne boje u nebulizatoru.
Data with intravenously administered iloprost indicated that the elimination is reduced in patients with renal failure requiring dialysis. 
Podaci o intravenskoj administraciji iloprosta ukazuju da je u bolesnika sa zatajenjem bubrega na dijalizi eliminacija smanjena.
Bayer OÜ Tel: +372 655 8565 
Tel: +372 655 8565
Serum glucose levels 
Razine glukoze u serumu
The I-Neb AAD System is a portable, hand-held, vibrating mesh technology nebuliser system. 
Sustav I-Neb AAD je prijenosni ručni nebulizatorski sustav s tehnologijom vibrirajuće mrežice.
Hepatic impairment Iloprost elimination is reduced in patients with hepatic dysfunction (see section 5.2). 
U bolesnika s poremećenom funkcijom jetre eliminacija iloprosta je smanjena (vidjeti dio 5.2).
In case of interruption of Ventavis therapy, the risk of rebound effect is not formally excluded. 
Rizik od pogoršanja simptoma bolesti u slučaju prekida liječenja lijekom Ventavis nije službeno isključen.
Keep this medicine out of the sight and reach of children. 
Kako čuvati Ventavis Lijek čuvajte izvan pogleda i dohvata djece.
In case of poor tolerability of the 5 microgram dose, the dose should be reduced to 2.5 microgram iloprost. 
U slučaju slabe podnošljivosti doze od 5 mikrograma, doza se mora smanjiti na 2,5 mikrograma iloprosta.
Ampoule coloured rings 
Ampula / obojeni prstenovi
Newborns, infants and pregnant women should not be subjected to Ventavis in the room air. 
Novorođenčad, dojenčad i trudnice ne smiju biti izloženi lijeku Ventavis koji se nalazi u zraku u prostoriji.
Ampoules with 1 ml nebuliser solution (for the use of Breelib or I-Neb AAD): 
Ampule s 1 ml otopine za nebulizator (za primjenu pomoću uređaja Breelib ili I-Neb AAD):
5 mcg 
5 µg